Kennedy defends peptide deregulation and brushes off vaccine criticism in tense hearings

Robert F. Kennedy Jr. stood his ground this week amid mounting scrutiny over his leadership at the Department of Health and Human Services. In two marathon budget hearings before Congress, Kennedy defended a push to reduce oversight of unapproved peptide therapies-lab-made chains of amino acids often marketed as anti-aging or performance-boosting treatments. While some in the wellness industry have celebrated the move, public health experts warn these substances lack rigorous testing and could put patients at risk.

Kennedy argued that current regulations stifle innovation and limit patient access to potentially beneficial therapies. He pointed to anecdotal reports and early-stage research as justification for a more permissive approach. But critics, including those from the Washington Monthly, say the policy shift prioritizes ideology over science and could open the door to widespread misuse. With little FDA oversight, there's growing concern that clinics may begin offering unproven, even dangerous, treatments under the guise of medical innovation.

The hearings also reignited debate over Kennedy's long-standing skepticism of vaccines. When asked whether he'd faced pressure from the White House to moderate his views, Kennedy said no. That response surprised some observers, given the administration's broader public health messaging. While he didn't repeat past controversial claims, he didn't disavow them either, instead redirecting focus to his peptide initiative and environmental health issues.

Tensions flared when Rep. Troy Carter (D-La.) suggested Kennedy spends too much time on fringe topics, referencing past comments about animal encounters involving whale heads and raccoon parts. "I wish you'd spend less time talking about whale heads, bear heads, and raccoon parts," Carter said. Kennedy shot back, calling the remark dismissive and racially charged, though he didn't elaborate. The exchange underscored the friction between Kennedy's unconventional communication style and congressional expectations.

Lawmakers from both parties voiced concern about the long-term impact of his policies. Republicans questioned funding allocations for the NIH and military medical readiness, while Democrats pressed on patient safeguards and scientific integrity. Despite the pushback, Kennedy remained confident, framing his agenda as a necessary challenge to entrenched bureaucracies.

Public reaction has been divided. Supporters see him as a disruptor breaking down barriers to alternative medicine. Critics argue he's normalizing unproven treatments at a time when trust in public health institutions remains fragile. With peptide clinics already expanding in states with looser regulations, the stakes are rising.

For now, Kennedy shows no sign of shifting course. Whether his approach leads to breakthroughs or blowback may depend on how well patient outcomes are tracked-and whether any high-profile harms emerge down the line.